PPARG and diabetes mellitus: Rutin shows high affinity with AKT1 and EGFR [53], and also with α-glucosidase and α-amylase [54]; luteolin with AKT1, VEGFA, NOS3, PPARG, MMP9, VCAM1, which has a high binding activity [55]; maritimetin has a good affinity with the diabetes drug target 5NN8 [56]; and polydatin also showed high affinity with PCSK9 and STING [41,57].